ReviewEuropean journal of nuclear medicine and molecular imaging2004
Apoptosis-detecting radioligands: current state of the art and future perspectives.
Review in European journal of nuclear medicine and molecular imaging, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 196 citations in OpenAlex.
- First-in-Man Evaluation ofMolecular imagingTrial
- Anti-proliferative and pro-apoptotic activity of glycosidic derivatives of lawsone in melanoma cancer cell.BMC cancer · 2021Article
- Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy.Journal of personalized medicine · 2020Review
- Roadmap toward the 10 ps time-of-flight PET challenge.Physics in medicine and biology · 2020Article
- In vivo magnetic resonance imaging of treatment-induced apoptosis.Scientific reports · 2019Article
- Avenues to molecular imaging of dying cells: Focus on cancer.Medicinal research reviews · 2018Review
- Ferumoxytol-based Dual-modality Imaging Probe for Detection of Stem Cell Transplant Rejection.Nanotheranostics · 2018Article
- An enhanced bioluminescence-based Annexin V probe for apoptosis detection in vitro and in vivo.Cell death & disease · 2017Article
- SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic.Oncotarget · 2017Review
- Development of a large peptoid-DOTA combinatorial library.Biopolymers · 2016Article
- 99mTc-labelled anti-CD11b SPECT/CT imaging allows detection of plaque destabilization tightly linked to inflammation.Scientific reports · 2016Article
- High-frequency ultrasound analysis of post-mitotic arrest cell death.Oncoscience · 2016Article
- Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine.Journal of magnetic resonance imaging : JMRI · 2015Article
- Magnetic resonance imaging of stem cell apoptosis in arthritic joints with a caspase activatable contrast agent.ACS nano · 2015Article
- Molecular PET Imaging of Cyclophosphamide Induced Apoptosis with 18F-ML-8.BioMed research international · 2015Article
- Molecular imaging of apoptosis: from micro to macro.Theranostics · 2015Review
- PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V.American journal of nuclear medicine and molecular imaging · 2015Article
- Production of recombinant human annexin V by fed-batch cultivation.BMC biotechnology · 2014Article
- A low molecular weight zinc2+-dipicolylamine-based probe detects apoptosis during tumour treatment better than an annexin V-based probe.European radiology · 2014Article
- Aptamers as both drugs and drug-carriers.BioMed research international · 2014Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides a critical and thorough overview of the radiopharmaceutical development and in vivo evaluation of all apoptosis-detecting radioligands that have emerged so far, along with their possible applications in nuclear medicine. The following SPECT and PET radioligands are discussed: all forms of halogenated Annexin V (i.e. (123)I-labelled, (124)I-labelled, (125)I-labelled, (18)F-labelled), (99m)Tc/(94m)Tc-labelled Annexin V derivatives using different chelators and co-ligands (i.e. BTAP, Hynic, iminothiolane, MAG(3), EDDA, EC, tricarbonyl, SDH) or direct (99m)Tc-labelling, (99m)Tc-labelled Annexin V mutants and (99m)Tc/(18)F-radiopeptide constructs (i.e. AFIM molecules), (111)In-DTPA-PEG-Annexin V, (11)C-Annexin V and (64)Cu-, (67)Ga- and (68)Ga-DOTA-Annexin V. In addition, the potential role and clinical relevance of anti-PS monoclonal antibodies and other alternative apoptosis markers are reviewed, including: anti-Annexin V monoclonal antibodies, radiolabelled caspase inhibitors and substrates and mitochondrial membrane permeability targeting radioligands. Nevertheless, major emphasis is placed on the group of Annexin V-based radioligands, in particular (99m)Tc-Hynic-Annexin V, since this molecule is by far the most extensively investigated and best-characterised apoptosis marker at present. Furthermore, the newly emerging imaging modalities for in vivo detection of programmed cell death, such as MRI, MRS, optical, bioluminescent and ultrasound imaging, are briefly described. Finally, some future perspectives are presented with the aim of promoting the development of potential new strategies in pursuit of the ideal cell death-detecting radioligand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.